Roche xCELLigence System for Cell Analysis to Provide Predictive Mechanistic Information for Small Molecule Compounds

Mannheim, (PresseBox) - The extent to which protein targets are modulated by drugs or small molecule compounds depends on a number of factors, including the expression levels of the target, the effective concentration of the compound, and the time needed for the compound to perturb the target. One of the limitations of current multidimensional phenotypic profiling approaches is that typically a single time point is chosen to assess the effect of compounds. The conclusion, regarding the compounds' mechanism of action, is based on the time point at which the samples are processed.

To address these restrictions, researchers Abassi et al. (1) have devised a live cell morphological profiling approach for dynamic monitoring of the effect of small molecule compounds that was based on impedance measurement of cells with the xCELLigence RTCA System of Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY). The approach was tested by screening a library containing FDA approved drugs, experimental compounds, and natural compounds. Compounds with similar activity produced similar impedance-based Time-dependent Cell Response Profiles (TCRPs). The compounds were clustered then based on TCRP similarity.

The researchers identified novel mechanisms for existing drugs, confirmed previously reported calcium modulating activity for COX-2 inhibitor celecoxib, and discovered an additional mechanism for the experimental compound monastrol. They also recognized and characterized a new antimitotic agent. This approach will also help to detect the off target effect of a given compound.

The TCRP technique described by Abassi et al. can overcome the limitations of current approaches, because the profile generated is time dependent. In combination with measurement of cell number, morphology, and adhesion, the TCR technique allows greater expansion of the ''biological space'' at which compounds are screened. It provides ample opportunity to detect and identify biological activity associated with small molecules.

In conclusion, these findings indicate that the time-dependant resolution, provided by the TCRP approach, can be used in conjunction with phenotypic profiling approaches to obtain additional data associated with small molecule compounds. TCRP approach provides predictive mechanistic information for small molecule compounds.

The non-invasive and label-free xCELLigence analysis method, originally invented by ACEA Biosciences in San Diego, USA is based on measuring the impedance of cells. The technique utilizes an electronic readout of impedance to non-invasively quantify cellular status in real-time. Cells are seeded in E-Plate microtiter plates, which are integrated with microelectronic sensor arrays. The interaction of cells with the microelectrode surface generates a cell-electrode impedance response, which not only indicates cell viability but also correlates with the number of the cells seeded in the well. In conjunction with its user-friendly data collection and analysis capabilities, the xCELLigence System makes a unique platform for continuous, real-time cell-based assays and provides a huge opportunity for cellular and molecular biology.

For more information on the technology, please visit www.roche-applied-science.com.

Literature:

(1) Abassi YA et al.: Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 2009; 16:712-723

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

XCELLIGENCE is a trademark of Roche.

E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.